Journal of Cardiac Failure

We are proud of the progress reflected in this year’s Impact Factor of 9.9, but even more proud of what all of this represents. A heartfelt THANK YOU to our entire JCF Family. Your engagement as authors, reviewers, readers, and mentors continues to drive this collective success.

🫀 The July edition of JCF is here! Featuring the latest perspectives and studies on heart failure and patient care. 🔗 Read the full issue: onlinejcf.com/current

🫀The July edition of JCF is here! Featuring the latest perspectives and studies on heart failure and patient care. 🔗 Read the full issue: onlinejcf.com/current

📣Call for Papers: JCF is accepting submissions for our focus issue: The New Frontier of Heart Function in Women. Research spanning the female lifespan, from reproductive health to HFpEF, prevention, and heart failure is encouraged. Submit by 9/15/26: bit.ly/4xQkPSR

Can LVADs do more than support circulation? This JCF Ignite! article explores whether LVAD-mediated unloading can promote reverse remodeling and myocardial recovery, and whether some patients might benefit from LVAD therapy as a bridge to regeneration. 🔗bit.ly/3S0UHEj

Editorial perspective: Palliative care is not just end-of-life care. This editorial argues for integrating symptom management, shared decision-making & GoC discussions earlier in advanced HF, making palliative care a core component of longitudinal HF care. bit.ly/4oltKXL

How should palliative care fit into advanced HF care? The HeartPal program embedded palliative care within an advanced heart disease service, resulting in earlier referrals, more GoC discussions, fewer late referrals & reduced in-hospital deaths. bit.ly/3S4btlS

🚨HF-CS is now more common than AMI-CS. This State-of-the-Art Review examines how microaxial flow pumps are reshaping HF-CS care through LV unloading, prolonged support, hemodynamic-guided management, and bridge-to-recovery/transplant strategies. 🫀📊 🔗 bit.ly/4ez3oye

🚨 What is the optimal MAP target in AMI-CS? This meta-analysis found no mortality benefit with higher MAP targets vs lower targets. 📊 The findings challenge a "higher is better" approach & highlight the need for individualized perfusion goals. ❤️‍🩹 🔗 bit.ly/4vL6dSW

📢 Call for Papers: The New Frontier of Heart Function in Women. Guest Editors Drs. Anuradha Lala, Martha Gulati, Novi Yanti Sari, and Diana de Oliveira-Gomes will lead this issue, publishing in February '27. Categories & topic areas: bit.ly/4vjovuq Submit by Sept. 15

Editorial perspective 📝 SURPASS highlights the promise of Impella 5.5 as a bridge to recovery, transplant, or durable LVAD. But important questions remain! Patient selection, timing, & support strategy may be just as important as the device itself. 🔗bit.ly/4avfPsr

New science 🚨: Impella 5.5 for HF-related cardiogenic shock 🫀 In the SURPASS registry (n=444), survival to discharge was 75% overall & 86.5% with Impella 5.5 alone. Patients bridged to transplant/LVAD had excellent outcomes, with >93% survival. 🔗bit.ly/4ecprJZ

🫀 Infiltrative & inflammatory cardiomyopathies share common pathways of dysfunction. Advanced imaging is shifting from structure→biology. Probing inflammation, microvascular dysfunction, and energetics to refine diagnosis and guide precision HF care. bit.ly/4v2Oi9I

Last call! 🚨 Submissions close today for JCF’s Focus Issue - Artificial Intelligence and Heart Failure: A Critical Juncture. Don’t miss the opportunity to contribute at this defining moment in HF care. 🫀 bit.ly/4kJl5gf #HeartFailure #AIinHealthcare #CallForPapers

What's new in heart failure research? Find out in the June edition of JCF, featuring expert perspectives advancing our understanding of heart failure and informing patient care. Read the full issue: onlinejcf.com/current

Time is running out to submit to JCF’s Focus Issue - Artificial Intelligence and Heart Failure: A Critical Juncture. If your work advances responsible innovation in HF care, now is the time to contribute.⌛ 🗓️ Deadline: June 15th, 2026 bit.ly/4kJl5gf #AIinHealthcare

In HELIOS-B, vutrisiran slowed renal decline in ATTR-CM: fewer ≥40% eGFR drops vs placebo (12.7% vs 21.2%). Benefits on CV outcomes were consistent across kidney function, even in advanced CKD. Improves not just CV outcomes but has renal benefits🫀🧪 bit.ly/3Q2hhf1

Cardiac sarcoidosis: beyond steroids? The REPAIR-CS trial is testing rilonacept (IL-1 blockade) added to standard therapy, with FDG-PET inflammation as the primary endpoint—marking a shift toward targeted, mechanism-based treatment.🫀 🔗 bit.ly/3RijCTs

But what does a positive biopsy mean? The editorial notes no association with outcomes, small high-risk subgroups & lack of genetic testing. EMB may be most valuable earlier, when diagnosis is uncertain and results can change management. 🔍 bit.ly/4dwNrqH

When should we biopsy for cardiac sarcoidosis? In ILLUMINATE-CS, EMB positivity (~22%) was directionally associated with established predictors (MIDFIN). Novel predictors: septal thickness, FDG-PET burden, BNP). EMBx yield rose stepwise with number of criteria. 🧵